141 related articles for article (PubMed ID: 38300162)
1. People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?
Bartalucci C; Baldi F; Ricci E; Orofino G; Menzaghi B; Ferrara S; Pellicano' GF; Squillace N; Sarchi E; Pontali E; Cenderello G; Bargiacchi O; Piccica M; Carleo MA; Cascio A; De Socio GV; Bonfanti P; Di Biagio A
AIDS; 2024 Mar; 38(3):430-434. PubMed ID: 38300162
[TBL] [Abstract][Full Text] [Related]
2. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lowenthal ED; Chapman J; Ohrenschall R; Calabrese K; Baltrusaitis K; Heckman B; Yin DE; Agwu AL; Harrington C; Van Solingen-Ristea RM; McCoig CC; Adeyeye A; Kneebone J; Chounta V; Smith-Anderson C; Camacho-Gonzalez A; D'Angelo J; Bearden A; Crauwels H; Huang J; Buisson S; Milligan R; Ward S; Bolton-Moore C; Gaur AH; ;
Lancet HIV; 2024 Apr; 11(4):e222-e232. PubMed ID: 38538161
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Gaur AH; Capparelli EV; Calabrese K; Baltrusaitis K; Marzinke MA; McCoig C; Van Solingen-Ristea RM; Mathiba SR; Adeyeye A; Moye JH; Heckman B; Lowenthal ED; Ward S; Milligan R; Samson P; Best BM; Harrington CM; Ford SL; Huang J; Crauwels H; Vandermeulen K; Agwu AL; Smith-Anderson C; Camacho-Gonzalez A; Ounchanum P; Kneebone JL; Townley E; Bolton Moore C; ;
Lancet HIV; 2024 Apr; 11(4):e211-e221. PubMed ID: 38538160
[TBL] [Abstract][Full Text] [Related]
4. Favorable Virological Outcome, Characteristics of Injection Site Reactions, Decrease in Renal Function Biomarkers in Asian People with HIV Receiving Long-Acting Cabotegravir Plus Rilpivirine.
Adachi E; Saito M; Otani A; Koga M; Yotsuyanagi H
AIDS Res Hum Retroviruses; 2024 Apr; 40(4):216-222. PubMed ID: 38164081
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of long-acting cabotegravir + rilpivirine for the treatment of virologically suppressed adults living with HIV.
Qazzaz H; Parganas C; Cory TJ
Expert Opin Pharmacother; 2022 Sep; 23(13):1485-1495. PubMed ID: 36124818
[TBL] [Abstract][Full Text] [Related]
6. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Orkin C; Bernal Morell E; Tan DHS; Katner H; Stellbrink HJ; Belonosova E; DeMoor R; Griffith S; Thiagarajah S; Van Solingen-Ristea R; Ford SL; Crauwels H; Patel P; Cutrell A; Smith KY; Vandermeulen K; Birmingham E; St Clair M; Spreen WR; D'Amico R
Lancet HIV; 2021 Nov; 8(11):e668-e678. PubMed ID: 34656207
[TBL] [Abstract][Full Text] [Related]
7. Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection.
Calleja-Hernández MÁ; Martinez-Sesmero JM; Vallejo-Aparicio LA; Hernández-Novoa B; Badia X
Farm Hosp; 2022 Jul; 46(4):208-214. PubMed ID: 36183218
[TBL] [Abstract][Full Text] [Related]
8. Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice.
Borghetti A; Farinacci D; Ciccullo A; Dusina A; Moschese D; Iannone V; D'Angelillo A; Lombardi F; Donne VD; Massaroni V; Visconti E; Tamburrini E; Di Giambenedetto S
J Med Virol; 2022 Oct; 94(10):4970-4974. PubMed ID: 35638227
[TBL] [Abstract][Full Text] [Related]
9. Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV.
Taki E; Soleimani F; Asadi A; Ghahramanpour H; Namvar A; Heidary M
Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1135-1147. PubMed ID: 35596583
[TBL] [Abstract][Full Text] [Related]
10. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
[TBL] [Abstract][Full Text] [Related]
11. Long-acting Injectable Cabotegravir/Rilpivirine Effective in a Small Patient Cohort With Virologic Failure on Oral Antiretroviral Therapy.
Brock JB; Herrington P; Hickman M; Hickman A
Clin Infect Dis; 2024 Jan; 78(1):122-124. PubMed ID: 37740255
[TBL] [Abstract][Full Text] [Related]
12. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
13. Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience.
Castelli A; Lanzafame M; Morra M; Bertoldi M; Delama A; Fait D; Vento S
AIDS Res Hum Retroviruses; 2024 May; 40(5):283-285. PubMed ID: 37776179
[TBL] [Abstract][Full Text] [Related]
14. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
[TBL] [Abstract][Full Text] [Related]
15. Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals.
Cossu MV; Cattaneo D; Moschese D; Giacomelli A; Soloperto S; D'Avolio A; Antinori S; Gori A; Rizzardini G; Gervasoni C
J Antimicrob Chemother; 2024 May; 79(5):1126-1132. PubMed ID: 38530862
[TBL] [Abstract][Full Text] [Related]
16. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
Chounta V; Snedecor SJ; Wu S; Van de Velde N
BMC Infect Dis; 2022 May; 22(1):428. PubMed ID: 35508986
[TBL] [Abstract][Full Text] [Related]
17. Monthly injectable cabotegravir/rilpivirine to manage HIV infection in adults.
Blackwell CW; López Castillo H
J Am Assoc Nurse Pract; 2022 Jul; 34(7):918-923. PubMed ID: 35580282
[TBL] [Abstract][Full Text] [Related]
18. Implementation of a Pharmacist-Led, Long-Acting, Injectable Cabotegravir/Rilpivirine Program for HIV-1 at Health System-Based Clinics in the New York Metropolitan Area.
Nguyen NM; Kavanagh R; Gozar M; Cabral D; Goetz H; Cha A; McGowan JP; Pao ML
AIDS Patient Care STDS; 2024 Mar; 38(3):115-122. PubMed ID: 38471090
[TBL] [Abstract][Full Text] [Related]
19. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
[TBL] [Abstract][Full Text] [Related]
20. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Jaeger H; Overton ET; Richmond G; Rizzardini G; Andrade-Villanueva JF; Mngqibisa R; Hermida AO; Thalme A; Belonosova E; Ajana F; Benn PD; Wang Y; Hudson KJ; Español CM; Ford SL; Crauwels H; Margolis DA; Talarico CL; Smith KY; van Eygen V; Van Solingen-Ristea R; Vanveggel S; Spreen WR
Lancet HIV; 2021 Nov; 8(11):e679-e689. PubMed ID: 34648734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]